Rev ALAD ; Looker HC, Nyangoma SO, Cromie D et al. Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland. Diabetologia Title: Revista ALAD Volumen 5 Número 1, Author: Asociacion Latinoamericana de Diabetes, En: 4th World Congr Controv Diabetes Obes Hypertens KDOQI Clinical Practice Guideline for Diabetes and CKD: update. Am J Kidney Dis ; Guías ALAD sobre el diagnóstico, control y.

Author: Grora Fenritaur
Country: Dominica
Language: English (Spanish)
Genre: Literature
Published (Last): 18 January 2014
Pages: 413
PDF File Size: 11.99 Mb
ePub File Size: 15.31 Mb
ISBN: 444-8-14942-249-6
Downloads: 40080
Price: Free* [*Free Regsitration Required]
Uploader: Tygoshura

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

There was a problem providing the content you requested

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes. Richter B, Bandeira-Echtler E, et al. Revista de la ALAD ; 3: Repaglinide versus nateglinide monotherapy: N Eng J Med ; Exercise for type 2 diabetes mellitus.

Effects of SGLT2 inhibitors on cardiovascular outcomes.

Br J Nutr Curr Med Res Opinion Fish oil in people with type 2 diabetes mellitus. Promoting weight loss in type II diabetes. Am J Clin Nutr, Physical activity and dianetes gain prevention. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.


Standars of medical care in diabetes,http: A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet plus exercise intervention. Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes mellitus. Urinary tract infections in patients with diabetes treated with dapagliflozin.

Physical activity and all-cause mortality across levels of overall and abdominal adiposity in European men and women: Herman W, et al. Basal insulin therapy in type 2 diabetes: A week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes in South and Central America: Systematic review of herbs and dietary supplements for glycemic control in diabetes.

Clarifying metformin’s role and risks in liver dysfunction. Primera Encuesta Nacional de Factores de Riesgo. Egan A, Blind E, et al.

Diabetes Eiabetes Syndr Obes ; 6: Revista de la ALAD, Managed care perspective on three new agents for type 2 diabetes.

Revista de la Sociedad Argentina de Diabetes Vol. Bailey C, Turner R.

Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in pregnant women with type 1 diabetes. Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in type 2 diabetes mellitus.


Approaches to treatment of type 2 diabetes.

Segunda Encuesta Nacional de Factores de Riesgo. Diabetes, obesity and metabolism Dietary advice for treatment of type 2 diabetes mellitus in adults;Pub 3, CD, Adv Ther ; N Engl J Med3: N Engl J Med Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: Mechanism by which metformin reduces glucose production in type 2 diabetes.

Diabetes Metab ; Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study.

Asociación Latinoamericana de Diabetes – ALAD

JAMA ; 1 Bariatric surgery versus intensive medical therapy for diabetesyear outcomes. Cochrane Database of Systematic Reviews. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Am J Med ; Cusi K, De Fronzo R.

How many, how fast, how good. Dipeptidylpeptidase 4 DPP-4 inhibitors for type 2 diabetes mellitus. Clinical practice guidelines for treatment of diabetes mellitus. Do we still need pioglitazone for the treatment of type 2 diabetes?